Thus, we recommend the use of TRK, CD34, and S-100 immunostaining as an accessible and cost-effective initial screening strategy for all uterine spindle cell tumors, particularly those lacking definitive endometrial stroma or smooth muscle differentiation, to facilitate the identification of NTRK-rearranged neoplasms. Here, NTRK1 is linked to neoplasm.